CuraTeQ Biologics receives UK MHRA approval for biosimilar Dyrupeg
Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQ's third biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024 and Zefylti in May 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
01-08-2025
- Hans India
Trump asks 17 non-Indian drug majors to cut prices in US; Nifty pharma dips
Mumbai: A letter from US President Donald Trump has asked 17 global drug giants to cut their prices in the country, sparking severe losses for them, as its impact hit the Indian stock market too. The letter urged that these businesses cut US drug pricing to match prices in other developed markets. Though no Indian pharmaceutical companies received Trump's letters, the Nifty Pharma index reacted sharply, falling 2.45 per cent during the intra-day trade on Friday. The index fell for the third day in a row. Sun Pharmaceutical Industries Ltd fell 3.98 per cent. Aurobindo Pharma lost 3.42 per cent and Granules India lost 3.2 per cent. Gland Pharma, Cipla, and Lupin fell 2 to 3 per cent. The US President wrote to 17 of the world's major pharmaceutical corporations, pressing them to lower drug prices immediately and give assurance that future drugs will be priced in line with other countries. The letters were sent to Eli Lilly, Novo Nordisk, Pfizer, and others, seeking 'Most Favoured Nation' (MFN) pricing for US within 60 days. White House Press Secretary Karoline Leavitt said recent data showed that Americans paid more than three times more for brand-name drugs than other developed nations. Trump had earlier made a similar announcement on May 12, asking pharma companies to cut prices in US. Industry sources in India had then said Trump's proposal might hurt Indian exporters of branded generics to the US, given generic drugs are already sold at low prices. If prices are cut further, it will make shipping unviable, they said. A third of Indian pharmaceutical exports of $30 billion annually, reach the US market. Trump gave drug companies 60 days to voluntarily comply with the new pricing diktat in the letter, failing which, he said, the US would use 'every tool in our arsenal' to protect Americans from 'continued abusive drug pricing' practices. Trump's letter required companies to sell certain drugs directly to patients at prices at which they are offered to third-party insurers.
The Hindu
15-07-2025
- The Hindu
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug
Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused on HIV medicines and majority owned by GSK with Pfizer and Shionogi as shareholders, and Medicines Patent Pool (MPP) extending their voluntary licensing agreement to enable access to long-acting injectable HIV treatment. It builds on the voluntary license for CAB LA for HIV pre-exposure prophylaxis (PrEP). The announcement, on extending their agreement, comes in the wake of an updated guidance from World Health Organization (WHO) recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option. Existing licensees Aurobindo, Cipla and Viatris will consequently be able to develop, manufacture and supply generic versions of CAB LA, for use in combination with long-acting rilpivirine, for the treatment of HIV-1 infection in adults and adolescents weighing at least 35kg subject to required regulatory approvals being obtained, Aurobindo Pharma said on Tuesday. Vice chairman and MD of Aurobindo Pharma K. Nithyananda Reddy said the company remains committed to leveraging its global supply capabilities to make the vital combination long-acting injection therapy widely available and affordable. The consideration by ViiV and MPP to include the private market in royalty-bearing countries is a critical step toward expanding access across both public and private sectors, he said.
Time of India
14-07-2025
- Time of India
UKHSA warns: How antidepressants and other drugs can raise your risk in hot weather
Summer sunshine feels great until your prescription starts working against you. The UK Health Security Agency (UKHSA) has sounded the alarm: common medications can impair your ability to cope with hot weather, increasing risks of dehydration, heat exhaustion, and even heatstroke. And this isn't just an elder-living-in-a-care-home problem—it's for anyone in sunny conditions taking these meds. Normally, your body cools itself by sweating, adjusting blood flow near your skin, and maintaining fluid balance. But certain medications mess with these systems and can throw your internal thermostat off balance. Take diuretics and blood pressure drugs like ACE inhibitors, beta-blockers, or calcium channel blockers. These meds can dehydrate you by increasing urination, suppressing thirst, and limiting blood flow shifts. That means less sweating, less cooling—and less ability to roll with soaring temps. The MHRA (Medicines and Healthcare products Regulatory Agency) specifically calls out these drugs as raising your heat risk during warm spells. Then you've got mental health drugs—SSRI and TCA antidepressants, antipsychotics, and ADHD stimulants like methylphenidate. They can stop your body from sweating enough, boost your core temperature, and make it harder for your brain to detect overheating. Even antibiotics like doxycycline ramp up sun sensitivity, making a short walk outside unexpectedly scorching. Meanwhile, NSAIDs and some supplements put extra stress on your kidneys during dehydration—meaning your meds can make the heat hit harder than usual. When pills go off script in the heat It's not just about side effects. Heat itself can degrade medication. Insulin, and certain antibiotics can become less effective if stored above recommended temps—usually around 25°C. Picture leaving your insulin vials baking in a hot car or your pills in a backpack at the beach. The MHRA warns these medications can lose potency, or even become dangerously unstable. Heatproofing your health routine So what should you do if you're on these meds and the thermometer spikes? Start with storing meds properly. Keep them out of direct sunlight, avoid cars in midday heat, and check that bottles haven't changed color or texture. Know where your fridge's cooler spots are, and move meds into them when needed. Then there's personal heat readiness. Stay hydrated and don't wait until you're thirsty—those on diuretics or antihypertensives might not feel typical thirst signals. Look out for dizziness, headaches, confusion, or dark urine: classic heat-exhaustion signs. If you're on any meds that affect your body's heat response—SSRIs, beta-blockers, ADHD meds—think ahead. Limit outdoor time during peak sun hours from 11am to 3pm. Stick to light clothing, stay in shade, and chill out indoors when the heat's too much. Who's most at risk? This isn't just doom-saying. Heat-health alerts like the UK's yellow and amber warnings are being issued more frequently, and the public health impact is real. England recorded over 1,300 heat-related deaths last summer, and medicines were a big contributor. Elderly people, kids, those with chronic conditions, or anyone on multiple medications—especially those for blood pressure, mental health, or diabetes—are the most vulnerable. But if you enjoy festivals, outdoor work, or travel, heat and pills could pose overlooked hazards. A prescription for summer safety What if everyone had a 'heat plan' alongside their morning meds? The CDC suggests that clinicians discuss temporary dose adjustments, hydration plans, and clear hot-weather check-ins with high-risk patients. Likewise, the UKHSA encourages pharmacists and health professionals to proactively reach out ahead of heatwaves with leaflets, alerts, and storage guidance. Even simple moves—keeping extra water by your bed, storing meds in a cool place, or turning on the fan during midday—can make a big difference when the mercury rises. Heat is a drug amplifier If you're breezing out in the sun this summer, your medication isn't just a pill in a cabinet—it's part of how your body reacts to heat. The UKHSA really isn't joking when they stress the double-whammy of high temps and everyday meds. Because in sweltering summer, keeping cool is about more than comfort—it's about staying safe while on the meds that help you live your best life.
